A Phase 1/2 Open-Label, Umbrella Platform Design Study to Evaluate the Safety and Efficacy of MK-2870 Plus Paclitaxel as the Second-Line Treatment of Participants With Advanced/Metastatic Gastroesophageal Adenocarcinoma: Substudy 06D
Latest Information Update: 15 Jun 2025
At a glance
- Drugs Paclitaxel (Primary) ; Ramucirumab (Primary) ; Sacituzumab Tirumotecan (Primary)
- Indications Adenocarcinoma; Gastric cancer; Oesophageal cancer
- Focus Adverse reactions; Therapeutic Use
- Acronyms Keymaker-U06
- Sponsors Merck Sharp & Dohme
Most Recent Events
- 30 Jul 2024 Planned initiation date changed from 1 Jul 2024 to 30 Jun 2024.
- 30 Jul 2024 Status changed from not yet recruiting to recruiting.
- 11 Jun 2024 New trial record